RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer
December 04 2019 - 8:00AM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage
immunology-based biopharmaceutical company focused on
discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in oncology and
inflammatory diseases, today announced the appointment of Rodney
Young as chief financial officer effective December 2, 2019.
“As a newly public company, we are thrilled to welcome Rodney to
RAPT,” said Brian Wong, M.D., Ph.D., president and CEO of RAPT
Therapeutics. “He is a seasoned executive who brings broad
strategic, operational and financial expertise to help biotech
companies grow successfully. Rodney will lead our finance and
administrative functions and work closely with the executive team
to guide the company’s development across all operational
areas.”
Mr. Young brings more than 30 years of executive management and
corporate finance experience. Most recently, he served as chief
financial officer of Cellerant Therapeutics, Inc., a private
clinical-stage company developing cell and antibody-based
immunotherapies for blood cancers and related disorders, where he
was responsible for accounting and financial management, and played
a key role in determining corporate strategy. Previously, he served
as chief financial officer and vice president of finance and
administration of StemCells, Inc., a public biotechnology company
developing stem cell therapeutics for central nervous system
disorders, where he was responsible for raising over $200 million
in financing. Earlier in his career, he was an investment banker at
Lehman Brothers and SG Cowen, leading financing and merger and
acquisition transactions focused in the healthcare, biotechnology,
and pharmaceutical sectors. Mr. Young received his MBA and BA from
the University of Chicago.
“RAPT has a compelling drug discovery platform that has
generated promising therapeutic drug candidates,” said Mr. Young.
“With an experienced team and thoughtful clinical development
plans, RAPT expects to have data from two compounds reading out in
2020. I’m thrilled to join the company at this important time.”
About RAPT Therapeutics, Inc.
RAPT Therapeutics (formerly FLX Bio) is a clinical stage
immunology-based biopharmaceutical company focused on discovering,
developing and commercializing oral small molecule therapies for
patients with significant unmet needs in oncology and inflammatory
diseases. Utilizing its proprietary discovery and development
engine, the company is developing highly selective small molecules
designed to modulate the critical immune responses underlying these
diseases. In its first four years since inception, RAPT has
discovered and advanced two unique drug candidates, each targeting
C-C motif chemokine receptor 4. The company’s lead oncology drug
candidate, FLX475, reached the clinic in just two and a half years
and RPT193, its lead inflammation drug candidate, is also in the
clinic. The company is also pursuing a range of targets, including
general control nonderepressible 2 and hematopoietic progenitor
kinase 1, that are in the discovery stage of development.
Media Contact:Angela Bittingmedia@rapt.com(925) 202-6211
Investor Contact:Sylvia Wheelerswheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Sep 2023 to Sep 2024